Healthcare · NSE: THYROCARE
Thyrocare Technologies
Q2 FY27 earnings and concall highlights
Q2 FY27 earnings call · Guided by management
Call held 29 Oct 2026 · Read the filing on NSEFiling
- M.Cap
- ₹8,112Cr
- P/E
- 56.3×
- 1Y return
- −2.24%
- From 52W high
- −23.0%
Highlights are read by AI from the company's filing and can contain mistakes. Check the source page linked to each line.
Share price
Results Q2 FY27, as filed · consolidated · ₹ Cr
| Q2 FY27 | Q2 FY26 | YoY | Q1 FY27 | QoQ | |
|---|---|---|---|---|---|
| Revenue | 271 | 217 | +25.1% | 240 | +12.8% |
| EBITDA | 89 | 71 | +25.1% | 77 | +15.6% |
| EBITDA margin | 33.0% | 33.0% | +2 bps | 32.2% | +78 bps |
| One-off items | -45 | — | — | — | — |
| PBTProfit before tax | 33 | 62 | -47.3% | 68 | -51.4% |
| Net profit | 16 | 48 | -66.9% | 52 | -69.6% |
| EPS (₹) | 0.95 | 9.03 | -89.5% | 3.22 | -70.5% |
From the company's own results filing on NSE. Net profit is the owners' share. Growth and the dotted lines are worked out from the filed figures.
Guidance
FY27 revenue growth now expected in the early 20s, up from mid-teens to high teens
Rahul Guha · Managing Director and Chief Executive Officer · Q&A · p. 21
FY27 revenue growth now expected in the early 20s, up from mid-teens to high teens
“With regards to revenue guidance, I had said mid-teens to high teens. I think now I think early 20s is a good estimate of where we think we'll end the year.”
Franchisee: No significant franchisee addition expected in Q3; normal pace hoped for in Q4
Rahul Guha · Managing Director and Chief Executive Officer · Q&A · p. 9
Franchisee: No significant franchisee addition expected in Q3; normal pace hoped for in Q4
“And that worked out very well for us, but I don't anticipate a significant addition in Q3. And I'm hopeful we will go back to our normal pace in Q4.”
Pregnancy kit: Pregnancy kit not expected to add to EPS for at least the next 3 quarters
Rahul Guha · Managing Director and Chief Executive Officer · Q&A · p. 10
Pregnancy kit: Pregnancy kit not expected to add to EPS for at least the next 3 quarters
“So I do not anticipate this being EPS accretive at least for the next 3 quarters, right, because we will do a lot of out-of-home media.”
More figures from the call
“So if you take a 5-year out view, a simple mathematics will be between 20,000 and 25,000 franchisees in 5 years.”
“This quarter, we added 5 new labs, 4 regional processing labs at Asansol, Nashik, Madurai, and Jabalpur, and 1 hybrid lab partnership at Jamshedpur.”
“Starting with the lab network, we now operate 48 labs in India and 1 in Tanzania.”
“laboratory network has expanded from 17 labs in FY21 to 49 labs today, of which 5 new laboratories were opened in Q2 FY27.”
“And even though I have been saying 31.5% to 32% margin in H1, we delivered 32.6% margin, so some of the operating leverage still came through.”
“And I've been saying that broadly 32% EBITDA was what we closed last year at. And I've been saying that we will maintain that range of EBITDA.”
In short
- 01FY27 revenue growth now expected in the early 20s, up from mid-teens to high teens.
- 02Long-term EBITDA margin anchored at about 31% to 31.5% while funding growth investments.
- 03Q2 FY27 consolidated revenue was Rs 271 crore, up 25%; pathology grew 27%.
- 04Radiology arm NHL to be sold to Trovera for Rs 141 crore; Rs 45 crore consolidated impairment taken.
- 05Company expects 1,500 to 2,000 franchisee additions a year; added about 1,180 in Q2.
- 06Specialty is about 4% of pathology revenue, targeted at 10% to 15% of revenue in 3 to 5 years.
- 07Pregnancy test kit launched; not expected to add to EPS for at least the next 3 quarters.
- 08H1 FY27 capex was Rs 30 crore, with similar capex expected in the rest of the year; net cash over Rs 211 crore.
Capex
Similar capex expected in the rest of FY27
Vikram Gupta · Chief Financial Officer · p. 8
Similar capex expected in the rest of FY27
“In balance part of the financial year, we are expecting a similar capex investment for the growth of the business.”
Specialty: Specialty testing capex was invested last financial year
Rajdeep Panwar · Chief Commercial Officer · Q&A · p. 15
Specialty: Specialty testing capex was invested last financial year
“We have started the testing. We have actually invested in the capex for this thing last financial year only.”
Segments
Specialty: Specialty currently about 4% of pathology revenue
Rahul Guha · Managing Director and Chief Executive Officer · p. 4
Specialty: Specialty currently about 4% of pathology revenue
“While the specialty segments currently contribute only around 4% of our pathology revenue, the early traction reflects the benefits of our strategic investments, enhanced in-house capabilities and continued expansion of our test menu.”
Pathology: Pathology business grew 27% in Q2 FY27
Rahul Guha · Managing Director and Chief Executive Officer · p. 3
Pathology: Pathology business grew 27% in Q2 FY27
“Continuing the growth momentum of over 20% achieved in each of the past 2 years, our pathology business grew even faster in Q2 FY27, delivering 27% growth.”
Franchisee: About 1,180 franchises added in Q2; active base 12,911
Rajdeep Panwar · Chief Commercial Officer · p. 5
Franchisee: About 1,180 franchises added in Q2; active base 12,911
“We added about 1,180 franchises in the quarter, our highest quarterly addition in 3 years, taking the active base of franchise to a record of 12,911.”
Partnership: Partnership business grew 28%, led by insurance and health tech
Rajdeep Panwar · Chief Commercial Officer · p. 6
Partnership: Partnership business grew 28%, led by insurance and health tech
“The business grew 28% year-on-year. Growth was led by insurance and health tech, along with continued scaling of existing accounts.”
Jaanch: Jaanch is 2.5% of pathology revenue and grew 58%
Rajdeep Panwar · Chief Commercial Officer · p. 5
Jaanch: Jaanch is 2.5% of pathology revenue and grew 58%
“While Jaanch is still only 2.5% of Pathology revenue, it grew by 58% and is fast becoming a strong pillar of our lifestyle portfolio.”
Demand
Company estimates 3 lakh to 4 lakh diagnostic centres in India
Rahul Guha · Managing Director and Chief Executive Officer · Q&A · p. 19
Company estimates 3 lakh to 4 lakh diagnostic centres in India
“I mean in our estimates, there are roughly between 3 lakh to 4 lakh diagnostic centres in the country.”
Margins and costs
Pregnancy kit: Pregnancy kit gross margin about comparable to diagnostics business
Rahul Guha · Managing Director and Chief Executive Officer · Q&A · p. 10
Pregnancy kit: Pregnancy kit gross margin about comparable to diagnostics business
“From an economic standpoint, I would say gross margin of this business is more or less comparable to our diagnostics business.”
Pregnancy kit: Kit launch costs about Rs 1.5 crore in Q2; another Rs 3 crore expected in Q3
Rahul Guha · Managing Director and Chief Executive Officer · Q&A · p. 17
Pregnancy kit: Kit launch costs about Rs 1.5 crore in Q2; another Rs 3 crore expected in Q3
“Roughly about INR1.5 crores has been incurred in Q2, and I expect to incur another INR3 crores in Q3.”
ESOP cost about Rs 4 crore in each of Q1 and Q2
Vikram Gupta · Chief Financial Officer · Q&A · p. 17
ESOP cost about Rs 4 crore in each of Q1 and Q2
“The ESOP cost is around INR4 crores in both Q1 and Q2.”
Employee and overhead costs rose due to inflation, volumes, labs and new areas
Vikram Gupta · Chief Financial Officer · p. 7
Employee and overhead costs rose due to inflation, volumes, labs and new areas
“Employees and other overheads increased year-on-year primarily due to inflation, higher volumes, lab expansion and investment in new growth areas like specialty and pregnancy kits.”
Pregnancy kit: Large out-of-home ad budget for pregnancy kit to launch after Diwali
Rahul Guha · Managing Director and Chief Executive Officer · Q&A · p. 18
Pregnancy kit: Large out-of-home ad budget for pregnancy kit to launch after Diwali
“On the sellout, as I indicated in my initial comments, we have a large out-of-home budget that will launch post Diwali.”
Debt and working capital
Net cash over Rs 211 crore and zero debt at 30 September 2026
Vikram Gupta · Chief Financial Officer · p. 8
Net cash over Rs 211 crore and zero debt at 30 September 2026
“Our balance sheet continues to be strong and resilient, with net cash and equivalents of over INR211 crores and zero debt as on 30 September 2026.”
Operating cash flow of Rs 133 crore in H1 FY27
Vikram Gupta · Chief Financial Officer · p. 8
Operating cash flow of Rs 133 crore in H1 FY27
“In cash flow, during H1 FY27, we generated INR133 crores from operating activities.”
Acquisitions and new business
NHL: NHL radiology business to be sold to Trovera for Rs 141 crore in cash and equity
Rahul Guha · Managing Director and Chief Executive Officer · p. 4
NHL: NHL radiology business to be sold to Trovera for Rs 141 crore in cash and equity
“we have initiated the process for the shareholders' approval for the disinvestment of NHL (our radiology business) for a consideration of INR141 crores to Trovera, which is a mix of cash of INR81.9 crores and equity of INR59.5 crores.”
NHL: Thyrocare ROCE 34.9% versus NHL ROCE 6.95%
Rahul Guha · Managing Director and Chief Executive Officer · p. 4
NHL: Thyrocare ROCE 34.9% versus NHL ROCE 6.95%
“The return on capital employed, ROCE, of Thyrocare is 34.9% and NHL ROCE is 6.95%.”
NHL: NHL lowers consolidated revenue growth by 2% and EBITDA margin by 1%
Rahul Guha · Managing Director and Chief Executive Officer · p. 5
NHL: NHL lowers consolidated revenue growth by 2% and EBITDA margin by 1%
“NHL is pulling the consolidated revenue growth rates and EBITDA margin down by 2% and 1%, respectively.”
NHL: NHL has low operating PAT and needs large investment as equipment nears end of life
Rahul Guha · Managing Director and Chief Executive Officer · p. 5
NHL: NHL has low operating PAT and needs large investment as equipment nears end of life
“NHL also has low operating PAT, and the investments required to continue Nueclear, as much of the equipment are at end of life is substantial.”
NHL: NHL still consolidated as wholly owned subsidiary in Q2 and H1
Vikram Gupta · Chief Financial Officer · p. 8
NHL: NHL still consolidated as wholly owned subsidiary in Q2 and H1
“Nueclear Healthcare Limited continues to be consolidated as a wholly owned subsidiary in H1 and the quarter financials.”
Dividends and buybacks
Company paid an interim dividend
Rahul Guha · Managing Director and Chief Executive Officer · Q&A · p. 19
Company paid an interim dividend
“On the dividend, yes, we have done an interim dividend.”
Final dividend to be decided later, as per policy
Rahul Guha · Managing Director and Chief Executive Officer · Q&A · p. 20
Final dividend to be decided later, as per policy
“and then decide what is the final dividend that we will move forward. And this will be as per policy.”
One-offs
NHL: NHL impairment of Rs 9 crore standalone and Rs 45 crore consolidated
Vikram Gupta · Chief Financial Officer · p. 8
NHL: NHL impairment of Rs 9 crore standalone and Rs 45 crore consolidated
“Separately, based on the latest valuation and term sheet, we have reassessed NHL's carrying value and taken an impairment of INR9 crores in Thyrocare standalone books and of INR45 crores in the consolidated financials against the goodwill arising from the acquisition of NHL.”
NHL: Impairment is non-recurring and non-cash, with no operational impact
Vikram Gupta · Chief Financial Officer · p. 8
NHL: Impairment is non-recurring and non-cash, with no operational impact
“Please note this is a non-recurring and non-cash charge and does not have any impact on the operational performance of the company.”
NHL: NHL consolidated carrying value about Rs 180 crore including goodwill
Vikram Gupta · Chief Financial Officer · Q&A · p. 17
NHL: NHL consolidated carrying value about Rs 180 crore including goodwill
“And the carrying value of the books is around INR83 crores net worth plus the goodwill, what is sitting in the financial at the time of consolidation altogether is coming around INR180 crores approximately.”
NHL: In FY20 NHL written down to about Rs 150 crore; Rs 44 crore standalone, Rs 6 crore consolidated impairment
Vikram Gupta · Chief Financial Officer · p. 8
NHL: In FY20 NHL written down to about Rs 150 crore; Rs 44 crore standalone, Rs 6 crore consolidated impairment
“In FY20, NHL's book value was written down to about INR150 crores in both standalone and consolidated books and for this, the company provided INR44 crores impairment in the standalone and INR6 crores impairment in the consolidated books as per Ind AS.”
Other
Pregnancy kit: Pregnancy kits made by two outsourced vendors under Thyrocare quality standards
Rahul Guha · Managing Director and Chief Executive Officer · Q&A · p. 10
Pregnancy kit: Pregnancy kits made by two outsourced vendors under Thyrocare quality standards
“With regard to the supply chain, we have two vendors who assemble and manufacture the kits for us, right, under stringent Thyrocare quality standards.”
Q2 consolidated revenue Rs 271 crore, up 25% year-on-year
Vikram Gupta · Chief Financial Officer · p. 7
Q2 consolidated revenue Rs 271 crore, up 25% year-on-year
“On a consolidated basis, revenue stood at INR271 crores, reflecting a robust 25% year-on-year growth.”
Q2 standalone revenue Rs 256 crore, up 26.7% year-on-year
Vikram Gupta · Chief Financial Officer · p. 7
Q2 standalone revenue Rs 256 crore, up 26.7% year-on-year
“Starting with revenue, our stand-alone revenue came in at INR256 crores, which is 26.7% up year-on-year.”
Q2 EBITDA margin 33%, EBITDA up 25% year-on-year
Vikram Gupta · Chief Financial Officer · p. 7
Q2 EBITDA margin 33%, EBITDA up 25% year-on-year
“Our EBITDA margin for the quarter was at 33% with year-on-year growth of 25%.”
96% of samples processed in NABL-accredited labs in the quarter
Ramesh Kinha · Chief Operating Officer · p. 7
96% of samples processed in NABL-accredited labs in the quarter
“With our NABL-accredited labs and continuous investments in the state-of-the-art equipment and upgrades, 96% of samples were processed in NABL-accredited labs this quarter.”
Sources
- Earnings call transcript, Q2 FY27 Filed 2 Nov 2026 · 21 pages
Management's own statements, quoted from its NSE filings. This page was read by AI and can contain mistakes: check the source pages before relying on any figure. No forecast or opinion of ours. Not investment advice.

